March 28th 2025
Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.
FDA panel votes to keep rosiglitazone on market, but wants label changes
July 20th 2010An FDA advisory panel voted 20?12 to recommend that the agency allow rosiglitazone (Avandia, GlaxoSmithKline) to remain on the market. However, most panelists want to see tougher warnings on the diabetes drug?s label, according to various media reports.
Diabetes prevention: Meta-analysis finds glitazones superior to other oral antidiabetic drug classes
July 15th 2010A systematic review assessing the comparative effectiveness of oral anti-diabetic drugs for preventing patients at high risk from progressing to type 2 diabetes has found glitazones (pioglitazone, rosiglitazone), biguanides (metformin), and alpha-glucosidase inhibitors (AGIs; acarbose, voglibose) reduced the relative risk of diabetes by as much as 63%, whereas insulin secretagogues (sulfonylureas and glinides) had no effect.
MTM bill seeks to help seniors manage medications, reduce healthcare costs
July 15th 2010Sens. Kay R. Hagan (D-N.C.) and Al Franken (D-Minn.) have introduced The Medication Therapy Management (MTM) Expanded Benefits Act, a bill that will allow seniors with one chronic illness to thoroughly review all their medications with a pharmacist in a one-on-one session.
FDA announces ongoing cardiovascular safety review of olmesartan
July 15th 2010FDA has announced that the agency is currently evaluating whether the use of the angiotensin II receptor blocker (ARB) olmesartan (Benicar, Daiichi Sankyo; also sold in combination with hydrocholorothiazide as Benicar HCT) was associated with increased cardiovascular mortality.
Overuse of antibiotics spurs vicious cycle
June 23rd 2010Patients whose doctors over-prescribe antibiotics may develop drug resistance that can last up to a year, putting them and others at risk when more serious treatment is needed, according to a study published in May in the British Medical Journal.